Literature DB >> 16518085

[Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213)].

Satoshi Tatemichi1, Kumi Kobayashi, Ayaka Maezawa, Mamoru Kobayashi, Yoshinobu Yamazaki, Nobuo Shibata.   

Abstract

The selectivity of silodosin (KMD-3213), an antagonist of alpha(1)-adrenoceptor (AR), to the subtypes (alpha(1A)-, alpha(1B)- and alpha(1D)-ARs) was examined by a receptor-binding study and a functional pharmacological study, and we compared its subtype-selectivity with those of other alpha(1)-AR antagonists. In the receptor-binding study, a replacement experiment using [(3)H]-prazosin was conducted using the membrane fraction of mouse-derived LM (tk-) cells in which each of three human alpha(1)-AR subtypes was expressed. In the functional pharmacological study, the following isolated tissues were used as representative organs with high distribution densities of alpha(1)-AR subtypes (alpha(1A)-AR: rabbit prostate, urethra and bladder trigone; alpha(1B)-AR: rat spleen; alpha(1D)-AR: rat thoracic aorta). Using the Magnus method, we studied the inhibitory effect of silodosin on noradrenaline-induced contraction, and compared it with those of tamsulosin hydrochloride, naftopidil and prazosin hydrochloride. Silodosin showed higher selectivity for the alpha(1A)-AR subtype than tamsulosin hydrochloride, naftopidil or prazosin hydrochloride (affinity was highest for tamsulosin hydrochloride, followed by silodosin, prazosin hydrochloride and naftopidil in that order). Silodosin strongly antagonized noradrenaline-induced contractions in rabbit lower urinary tract tissues (including prostate, urethra and bladder trigone, with pA(2) or pKb values of 9.60, 8.71 and 9.35, respectively). On the other hand, the pA(2) values for antagonism of noradrenaline-induced contractions in rat isolated spleen and rat isolated thoracic aorta were 7.15 and 7.88, respectively. Selectivity for lower urinary tract was higher for silodosin than for the other alpha(1)-AR antagonists. Our data suggest that silodosin has a high selectivity for the alpha(1A)-AR subtype and for the lower urinary tract.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16518085     DOI: 10.1248/yakushi.126.209

Source DB:  PubMed          Journal:  Yakugaku Zasshi        ISSN: 0031-6903            Impact factor:   0.302


  29 in total

1.  Efficacy of silodosin in the treatment of distal ureteral stones 4 to 10 mm in diameter.

Authors:  Mustafa Yuksel; Serdar Yilmaz; Husnu Tokgoz; Soner Yalcinkaya; Serkan Baş; Tümay Ipekci; Ali Yildiz; Nihat Ates; Murat Savas
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 2.  Efficacy and safety of silodosin in the medical expulsion therapy for distal ureteral calculi: a systematic review and meta-analysis.

Authors:  Wei Huang; Peng Xue; Huantao Zong; Yong Zhang
Journal:  Br J Clin Pharmacol       Date:  2015-09-21       Impact factor: 4.335

3.  Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2009

4.  Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2009

5.  Side Effects of alpha-Blocker Use: Retrograde Ejaculation.

Authors:  Steven A Kaplan
Journal:  Rev Urol       Date:  2009

Review 6.  The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis.

Authors:  Yuanshan Cui; Huantao Zong; Yong Zhang
Journal:  Int Urol Nephrol       Date:  2012-08-24       Impact factor: 2.370

Review 7.  Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.

Authors:  Monique P Curran
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 8.  The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.

Authors:  Júlio Fonseca; Carlos Martins da Silva
Journal:  Clin Drug Investig       Date:  2015-02       Impact factor: 2.859

Review 9.  Silodosin is effective for treatment of LUTS in men with BPH: a systematic review.

Authors:  Hui Ding; Wan Du; Zi-Zhen Hou; Han-Zhang Wang; Zhi-Ping Wang
Journal:  Asian J Androl       Date:  2012-12-10       Impact factor: 3.285

Review 10.  Silodosin in the treatment of benign prostatic hyperplasia.

Authors:  Maxime Rossi; Thierry Roumeguère
Journal:  Drug Des Devel Ther       Date:  2010-10-27       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.